Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 11 studies | 23% ± 6% | |
ciliated cell | 11 studies | 29% ± 11% | |
oligodendrocyte | 10 studies | 26% ± 10% | |
smooth muscle cell | 9 studies | 19% ± 4% | |
pericyte | 9 studies | 19% ± 3% | |
basal cell | 7 studies | 24% ± 7% | |
epithelial cell | 6 studies | 33% ± 19% | |
oligodendrocyte precursor cell | 6 studies | 28% ± 9% | |
plasmacytoid dendritic cell | 6 studies | 19% ± 3% | |
fibroblast | 5 studies | 20% ± 5% | |
type I pneumocyte | 4 studies | 20% ± 2% | |
classical monocyte | 4 studies | 23% ± 7% | |
non-classical monocyte | 4 studies | 23% ± 10% | |
retinal cone cell | 4 studies | 30% ± 6% | |
retinal rod cell | 4 studies | 22% ± 5% | |
astrocyte | 4 studies | 24% ± 7% | |
endothelial cell of lymphatic vessel | 3 studies | 18% ± 1% | |
ionocyte | 3 studies | 25% ± 3% | |
hematopoietic precursor cell | 3 studies | 21% ± 8% | |
retinal bipolar neuron | 3 studies | 23% ± 4% | |
precursor B cell | 3 studies | 20% ± 2% | |
myofibroblast cell | 3 studies | 18% ± 3% | |
GABAergic neuron | 3 studies | 24% ± 4% | |
dendritic cell | 3 studies | 27% ± 13% | |
natural killer cell | 3 studies | 16% ± 1% | |
abnormal cell | 3 studies | 20% ± 4% | |
CD16-positive, CD56-dim natural killer cell, human | 3 studies | 17% ± 1% | |
neuron | 3 studies | 31% ± 12% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 4500.11 | 1445 / 1445 | 100% | 43.27 | 183 / 183 |
ovary | 100% | 4230.31 | 180 / 180 | 100% | 47.54 | 430 / 430 |
stomach | 100% | 3270.85 | 359 / 359 | 100% | 38.50 | 286 / 286 |
lung | 100% | 4121.52 | 578 / 578 | 100% | 43.88 | 1153 / 1155 |
prostate | 100% | 4356.75 | 245 / 245 | 100% | 40.95 | 501 / 502 |
thymus | 100% | 4396.89 | 653 / 653 | 100% | 57.52 | 603 / 605 |
brain | 100% | 2163.18 | 2631 / 2642 | 100% | 66.04 | 705 / 705 |
intestine | 100% | 5088.76 | 966 / 966 | 99% | 34.76 | 523 / 527 |
pancreas | 100% | 2245.65 | 327 / 328 | 99% | 36.75 | 177 / 178 |
breast | 100% | 3770.67 | 459 / 459 | 99% | 67.96 | 1108 / 1118 |
bladder | 100% | 5014.00 | 21 / 21 | 99% | 34.00 | 499 / 504 |
kidney | 100% | 3078.88 | 89 / 89 | 99% | 46.15 | 890 / 901 |
uterus | 100% | 5478.74 | 170 / 170 | 98% | 38.70 | 451 / 459 |
skin | 100% | 2825.68 | 1807 / 1809 | 94% | 42.03 | 446 / 472 |
adrenal gland | 100% | 4269.48 | 258 / 258 | 93% | 24.33 | 214 / 230 |
liver | 98% | 1134.10 | 222 / 226 | 72% | 15.78 | 293 / 406 |
adipose | 100% | 3325.44 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 4203.25 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 19.27 | 29 / 29 |
muscle | 100% | 5506.15 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 3098.30 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 38.89 | 45 / 45 |
heart | 98% | 2958.04 | 847 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 85% | 1618.09 | 794 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 79% | 18.63 | 63 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0001885 | Biological process | endothelial cell development |
GO_0001525 | Biological process | angiogenesis |
GO_0006968 | Biological process | cellular defense response |
GO_0045603 | Biological process | positive regulation of endothelial cell differentiation |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0001228 | Molecular function | DNA-binding transcription activator activity, RNA polymerase II-specific |
GO_0000977 | Molecular function | RNA polymerase II transcription regulatory region sequence-specific DNA binding |
GO_0005515 | Molecular function | protein binding |
GO_0000981 | Molecular function | DNA-binding transcription factor activity, RNA polymerase II-specific |
GO_0046872 | Molecular function | metal ion binding |
Gene name | VEZF1 |
Protein name | Vascular endothelial zinc finger 1 (Putative transcription factor DB1) (Zinc finger protein 161) Vascular endothelial zinc finger 1 |
Synonyms | ZNF161 DB1 |
Description | FUNCTION: Possible transcription factor. Specifically binds to the CT/GC-rich region of the interleukin-3 promoter and mediates tax transactivation of IL-3. . |
Accessions | ENST00000584396.5 ENST00000583932.1 J3QLN5 ENST00000258963.7 J3QSH4 J9JIC7 ENST00000581208.2 Q14119 |